GB9516572D0 - Prevention and/or treatment of disease - Google Patents

Prevention and/or treatment of disease

Info

Publication number
GB9516572D0
GB9516572D0 GBGB9516572.6A GB9516572A GB9516572D0 GB 9516572 D0 GB9516572 D0 GB 9516572D0 GB 9516572 A GB9516572 A GB 9516572A GB 9516572 D0 GB9516572 D0 GB 9516572D0
Authority
GB
United Kingdom
Prior art keywords
disease
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9516572.6A
Other versions
GB2304048A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9516572A priority Critical patent/GB2304048A/en
Publication of GB9516572D0 publication Critical patent/GB9516572D0/en
Priority to AU67469/96A priority patent/AU6746996A/en
Priority to PCT/GB1996/001968 priority patent/WO1997006820A1/en
Publication of GB2304048A publication Critical patent/GB2304048A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
GB9516572A 1995-08-12 1995-08-12 Medicament containing saliva extract Withdrawn GB2304048A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9516572A GB2304048A (en) 1995-08-12 1995-08-12 Medicament containing saliva extract
AU67469/96A AU6746996A (en) 1995-08-12 1996-08-12 Antiviral compositions and methods
PCT/GB1996/001968 WO1997006820A1 (en) 1995-08-12 1996-08-12 Antiviral compositions and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516572A GB2304048A (en) 1995-08-12 1995-08-12 Medicament containing saliva extract

Publications (2)

Publication Number Publication Date
GB9516572D0 true GB9516572D0 (en) 1995-10-11
GB2304048A GB2304048A (en) 1997-03-12

Family

ID=10779168

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9516572A Withdrawn GB2304048A (en) 1995-08-12 1995-08-12 Medicament containing saliva extract

Country Status (3)

Country Link
AU (1) AU6746996A (en)
GB (1) GB2304048A (en)
WO (1) WO1997006820A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2380128A (en) * 2001-09-26 2003-04-02 Oladiran Lawoye Definite and absolute cure against HIV and AIDS
RU2276988C2 (en) * 2004-01-15 2006-05-27 Сергей Иванович Черныш Antiviral substance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB881530A (en) * 1958-10-23 1961-11-01 Teikoku Hormone Mfg Co Ltd Process for the manufacture of a new physiologically active substance from human or cattle saliva
FR4248M (en) * 1965-03-02 1966-06-27
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
WO1985004418A1 (en) * 1984-03-27 1985-10-10 Transgene S.A. Vectors for the expression of hirudine, transformed cells and process for the preparation of hirudine
RU2092183C1 (en) * 1988-05-26 1997-10-10 Ника Хелт Продактс Лимитед (Лихтенштейн) Antiviral or antibacterial composition and a method of its using
DE3819078A1 (en) * 1988-06-04 1989-12-07 Hoechst Ag AMBLYOMMIN, A NEW ACTIVE SUBSTANCE FOR ANTICOAGULATION THERAPY
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
NL8900943A (en) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V PROTEASE INHIBITOR.
ES2059666T3 (en) * 1989-10-06 1994-11-16 Mucos Emulsions Gmbh USE OF CATABOLIC ENZYMES FOR THE TREATMENT OF AN HIV INFECTION.
IL119491A (en) * 1991-09-05 2000-11-21 Schering Ag cDNA or DNA encoding a protein which inhibits collagen-induced platelet aggregation
HU220301B (en) * 1992-12-04 2001-11-28 Schering Ag. Clotting inhibitor made from protostomia saliva

Also Published As

Publication number Publication date
WO1997006820A1 (en) 1997-02-27
AU6746996A (en) 1997-03-12
GB2304048A (en) 1997-03-12

Similar Documents

Publication Publication Date Title
HK1094535A1 (en) Prevention and treatment of amyloidogenic disease
ZA965088B (en) Methods of preventing or treating allergles
HUP9601808A3 (en) Treatment of arteriosclerosis and xanthoma
AU7397094A (en) Prevention and treatment of alzheimer's disease
IL138692A0 (en) Treatment and prevention of vascular disease
IL141211A0 (en) Prevention and treatment of viral disease
AU6168296A (en) Chloroquine analogs and methods of preventing and treating p lasmodial disease
EP0833641A4 (en) Treatment and prevention of prostatic disease
EP0800396A4 (en) Treatment of hyperandrogenic conditions
SG47093A1 (en) Treatment and prevention of prostatic cancer
PL322002A1 (en) Variants of human dnase i
GB9516572D0 (en) Prevention and/or treatment of disease
AU6852896A (en) Diagnosis and treatment of neurological disease
GB9510961D0 (en) Hemorrhoid treatment and prevention
GB9502689D0 (en) Prevention and treatment of dementia
GB9520494D0 (en) Treatment of medical conditions
GB9520495D0 (en) Treatment of medical conditions
GB9520496D0 (en) Treatment of medical conditions
AU2003203740A1 (en) Prevention and treatment of amyloidogenic disease
EG20171A (en) Treatment of conditions and disease
IL118475A0 (en) Treatment of skin spots and prevention of their formation
ZA9810932B (en) Prevention of and treatment of amyloidogenic disease.
GB9522475D0 (en) Treatment of raynauds phenomenon
GB9410969D0 (en) Hemorrhoid treatment and prevention
ZA937015B (en) Treatment and diagnosis of cancer

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)